Our results indicating that the function of IGFBP-3 is either pro- or anti-tumorigenic depending on levels of GRP78, suggest that the key to improving the clinical outcome of patients is to implement measurement of both markers in breast tumours in clinical practice. This evidence concerns the gene HSPA5 and breast neoplasm.